A decision by the Federal Court of Appeal of Canada is restoring the availability of Ruzurgi (amifampridine) to treat…
Articles by Mary Chapman
While unhappy with shortcomings in the legislation, the National Organization for Rare Disorders (NORD) nonetheless is applauding a year-end…
The National Organization for Rare Disorders (NORD) is requesting applications from patient advocacy organizations to host new or existing…
The National Organization for Rare Disorders (NORD) is leading an effort by organizations representing or treating people with rare diseases,…
Catalyst Pharmaceuticals has been named BioFlorida’s David J. Gury Company of the Year for its breakthrough Lambert-Eaton myasthenia…
The National Organization for Rare Disorders’ (NORD) “Living Rare, Living Stronger Patient and Family Forum” is back in person…
A federal appeals court in the U.S. has issued a mandate that effectively vacates the 2019 regulatory approval of Jacobus…
At its first virtual investor event, biotech company Centogene set a bold mission: to cure 100 rare diseases…
To help patient advocacy leaders and their partners better understand how global health statistics codes — known as ICD codes…
Those who wish to gain practical tools for living optimally with rare diseases are encouraged to attend the annual…